Drugs.com - Clinical Trials Clinical trial news from Drugs.com. Comprehensive and up-to-date drug news for both consumers and healthcare professionals.
- Clinical Study Identifies Personalized Treatment Options for Metastatic Non-Small Cell Lung Cancer With Plasma Proteome Testingon April 25, 2024 at 4:04 pm
FORT MYERS, Fla., April 25, 2024. Florida Cancer Specialists & Research Institute, LLC (FCS) medical oncologist and hematologist Ernesto Bustinza-Linares, MD is co-author of a recent abstract published in the American Society of Clinical...
- Lykos Therapeutics Announces Completion of European Phase 2 Study for MDMA-Assisted Therapy for PTSDon April 24, 2024 at 9:04 pm
SAN JOSE, Calif., April 24, 2024. Lykos Therapeutics (formerly MAPS Public Benefit Corporation) ("Lykos"), a company dedicated to transforming mental healthcare, announced the completion of a European Phase 2 study (MP18), an open-label, multicenter...
- Endevica Bio drug candidate shows success in weight loss in new studyon April 23, 2024 at 11:04 pm
NORTHBROOK, Ill., April 23, 2024 - Endevica Bio, a company developing first-in-class peptide drug candidates, announced its novel weight-loss treatment was successful in a recent diet-induced obesity (DIO) rat study. This latest research solidifies...
- FDA Approves Clinical Trial for GFH925 Monotherapy in Phase III Registrational Study Treating Metastatic Colorectal Canceron April 22, 2024 at 4:04 am
SHANGHAI, April 19, 2024. GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food and Drug Administration (FDA) has granted the clinical trial approval for GFH925...
- Doctors Underutilize Next-Gen Antibiotics to Fight Resistant Infections in U.S. Hospitalson April 19, 2024 at 4:04 am
April 19, 2024 -- Despite Food and Drug Administration (FDA)-approval of seven next-generation antibiotics to fight infections caused by resistant “gram-negative” bacteria, clinicians frequently continue to treat antibiotic-resistant...
- AskBio Receives FDA Fast Track Designation for AB-1002 Investigational Gene Therapy Program in Congestive Heart Failureon April 18, 2024 at 11:04 pm
Berlin, Germany, and Research Triangle Park, NC, USA, April 18, 2024 – Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that...
- NIH Researchers Develop AI Tool with Potential to More Precisely Match Cancer Drugs to Patientson April 18, 2024 at 11:04 pm
April 18, 2024 -- In a proof-of-concept study, researchers at the National Institutes of Health (NIH) have developed an artificial intelligence (AI) tool that uses data from individual cells inside tumors to predict whether a person’s cancer...
- Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Painon April 18, 2024 at 4:04 am
BOSTON--(BUSINESS WIRE)--Apr. 18, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced important advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute and...
- BiVictriX Announces FDA Orphan Drug Designation and Completion of FDA INTERACT Meeting for BVX001 in the Treatment of Acute Myeloid Leukemiaon April 17, 2024 at 5:04 am
Alderley Park, 17 April 2024 – BiVictriX Therapeutics plc (AIM: BVX), a biotechnology company developing novel, next-generation bispecific Antibody Drug Conjugates (bxADCs) which are designed to offer substantially improved cancer cell...
- EAGLE-1 Phase III Data Show Potential for Gepotidacin as a New Oral Treatment Option for Uncomplicated Urogenital Gonorrhoea (GC) Amid Growing Resistance to Existing Treatmentson April 17, 2024 at 4:04 am
17 April 2024 -- GSK plc (LSE/NYSE: GSK) today announced positive results from the pivotal EAGLE-1 phase III trial for gepotidacin, a potential first-in-class oral antibiotic with a novel mechanism of action for uncomplicated urogenital gonorrhoea...
- Arrivo Bio Initiates Large Phase 2b Clinical Trial in Major Depressive Disorder with Novel SIRT6 Activator SP-624on April 16, 2024 at 4:04 am
MORRISVILLE, N.C.--(BUSINESS WIRE) April 16, 2024 -- Arrivo BioVentures announced today a significant step forward in the fight against major depressive disorder (MDD) with the dosing of the first patient in the SP-624-202 clinical trial. This...
- TLX101-CDx (Pixclara) Granted FDA Fast Track Designationon April 16, 2024 at 2:04 am
Melbourne (Australia) | 16 April 2024 -- Telix today announces that the United States (U.S.) Food and Drug Administration (FDA) has granted Fast Track designation1 for the Company’s investigational glioma imaging product, TLX101-CDx...
- The United States FDA Awards Orphan Drug Designation (ODD) to NM5072 for Treating Paroxysmal Nocturnal Hemoglobinuria (PNH)on April 15, 2024 at 7:04 pm
CLEVELAND, April 15, 2024 (GLOBE NEWSWIRE) -- NovelMed today announced that the Food and Drug Administration (FDA) has awarded Orphan Drug Designation (ODD) to NM5072, an Alternative Pathway (AP) blocker anti-Properdin antibody, for the...
- PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submissionon April 11, 2024 at 11:04 pm
TARRYTOWN, New York, April 11, 2024 – via IBN – PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the completed execution of its three pivotal...
- Study Reveals No Causal Link Between Neurodevelopmental Disorders and Acetaminophen Exposure Before Birthon April 11, 2024 at 3:04 am
April 11, 2024 -- Study reveals no causal link between neurodevelopmental disorders and acetaminophen exposure before birth. NIH-funded research in siblings finds previously reported connection is likely due to other underlying...
- AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Canceron April 10, 2024 at 11:04 pm
OCALA, Fla., April 10, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced top-line interim data indicating that combining Ampligen (rintatolimod) with Keytruda (pembrolizumab) in the treatment of recurrent...
- Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndromeon April 10, 2024 at 4:04 am
CAMBRIDGE, Mass.--(BUSINESS WIRE) April 10, 2024 -- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced interim data from the ongoing Phase 2 HELIOS clinical trial of AMX0035 (sodium...
- Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Heartson April 9, 2024 at 7:04 pm
PONTE VEDRA, Fla., April 9, 2024 — Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes,...
- NRx Pharmaceuticals Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depressionon April 9, 2024 at 5:04 am
RADNOR, Pa., April 8, 2024. NRx Pharmaceuticals, Inc. ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that the Company has achieved data-lock in its Phase 2b/3 Suicidal Treatment Resistant Bipolar...
- Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA Gene Overexpressionon April 9, 2024 at 4:04 am
CAMBRIDGE, Mass.--(BUSINESS WIRE) April 09, 2024 -- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the...